Quick Answer
REVIVA PHARMACEUTICALS HOLDINGS, INC. reported Net Income of -$19.86 million for fiscal year 2025.
REVIVA PHARMACEUTICALS HOLDINGS, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$19.86M +33.6% |
-$29.92M +23.8% |
-$39.26M -38.9% |
-$28.26M -231.6% |
-$8.52M -1479.2% |
$617.9K +7.6% |
| Total Assets | $15.92M +2.7% |
$15.50M -34.6% |
$23.70M +25.2% |
$18.92M -39.7% |
$31.40M -48.5% |
$61.02M -7.0% |
| Cash and Equivalents | $14.44M +7.1% |
$13.48M -42.3% |
$23.37M +26.2% |
$18.52M -37.6% |
$29.69M +42754.6% |
$69.3K -77.9% |
| Stockholders Equity | $8.65M +964.2% |
$812.6K -49.6% |
$1.61M -90.8% |
$17.56M -38.8% |
$28.69M +473.7% |
$5.00M -0.0% |
| R&D Expense | $11.71M -48.9% |
$22.91M -27.1% |
$31.42M +37.4% |
$22.87M +371.4% |
$4.85M +1543.8% |
$295.1K +50.8% |
| Operating Income | -$20.20M +34.4% |
-$30.80M +22.0% |
-$39.50M -39.9% |
-$28.23M -179.4% |
-$10.10M -1294.2% |
-$724.7K -374.3% |
| Shares Outstanding | 5.87M +148.9% |
2.36M -91.5% |
27.92M +36.5% |
20.45M +41.7% |
14.43M +433.7% |
2.70M +3.9% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$4.01M | +52.1% | +33.7% |
| Total Assets | September 30, 2025 | $14.33M | +87.8% | +23.2% |
| Cash and Equivalents | September 30, 2025 | $13.18M | +137.2% | +27.2% |
| Stockholders Equity | September 30, 2025 | $4.55M | +145.6% | +1090.9% |
| R&D Expense | September 30, 2025 | $2.13M | -68.9% | -42.8% |
| Operating Income | September 30, 2025 | -$4.03M | +52.4% | +33.6% |
| Shares Outstanding | September 30, 2025 | 96.34M | +188.1% | +41.7% |
- REVIVA PHARMACEUTICALS HOLDINGS, INC. reported Net Income of -$19.86 million for fiscal year 2025.
- REVIVA PHARMACEUTICALS HOLDINGS, INC. showed an increase of +33.6% in Net Income compared to the prior fiscal year.
- REVIVA PHARMACEUTICALS HOLDINGS, INC. reported Total Assets of $15.92 million for fiscal year 2025.
- REVIVA PHARMACEUTICALS HOLDINGS, INC. showed an increase of +2.7% in Total Assets compared to the prior fiscal year.
- REVIVA PHARMACEUTICALS HOLDINGS, INC. reported Cash and Equivalents of $14.44 million for fiscal year 2025.
- REVIVA PHARMACEUTICALS HOLDINGS, INC. showed an increase of +7.1% in Cash and Equivalents compared to the prior fiscal year.
- REVIVA PHARMACEUTICALS HOLDINGS, INC. reported Stockholders Equity of $8.65 million for fiscal year 2025.
- REVIVA PHARMACEUTICALS HOLDINGS, INC. showed an increase of +964.2% in Stockholders Equity compared to the prior fiscal year.
- REVIVA PHARMACEUTICALS HOLDINGS, INC. reported R&D Expense of $11.71 million for fiscal year 2025.
- REVIVA PHARMACEUTICALS HOLDINGS, INC. showed a decrease of -48.9% in R&D Expense compared to the prior fiscal year.
- REVIVA PHARMACEUTICALS HOLDINGS, INC. reported Operating Income of -$20.20 million for fiscal year 2025.
- REVIVA PHARMACEUTICALS HOLDINGS, INC. showed an increase of +34.4% in Operating Income compared to the prior fiscal year.
- REVIVA PHARMACEUTICALS HOLDINGS, INC. reported Shares Outstanding of 5.87 million shares for fiscal year 2025.
- REVIVA PHARMACEUTICALS HOLDINGS, INC. showed an increase of +148.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: